Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: Results from the IMPACT-HAP study

Critical Care

Volumn 18, Issue 3, 2014, Pages

  Peyrani, Paula ^a   Wiemken, Timothy L ^a   Kelley, Robert ^a   Zervos, Marcus J ^b   Kett, Daniel H ^c,d   File Jr , Thomas M ^e   Stein, Gary E ^f   Ford, Kimbal D ^g   Scerpella, Ernesto G ^g   Welch, Verna ^g   Ramirez, Julio A ^a   Arnold, Forest W ^h   Nakamatsu, Raul ^h   Uppatla, Srinivas ^h   Peddapalli, Sridivya ^h   Arshad, Samia ^h   Haque, Nadia ^h   Donabedian, Susan ^h   Cano, Ennie L ^h   Cubillos, G Fernando ^h   Pasquale, Timothy ^h   Jabrocki, Bonnie ^h   Salstrom, Sara Jane ^h   Smith, Curtis L ^h   more..

^a University of Louisville School of Medicine   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d JACKSON MEMORIAL HOSPITAL   (United States)

^e SUMMA HEALTH SYSTEM   (United States)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g PFIZER INC   (United States)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; VANCOMYCIN; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ADULT; ANEMIA; APACHE; ARTICLE; DRUG SAFETY; FEMALE; HUMAN; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TRACHEAL ASPIRATION PROCEDURE; VENTILATOR ASSOCIATED PNEUMONIA; CHEMICALLY INDUCED; CLINICAL TRIAL; KIDNEY DISEASE; MICROBIOLOGY; MORTALITY; MULTICENTER STUDY; PNEUMONIA, VENTILATOR-ASSOCIATED; TREATMENT OUTCOME;

ACETAMIDES; ADULT; ANEMIA; ANTI-BACTERIAL AGENTS; APACHE; FEMALE; HUMANS; KIDNEY DISEASES; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PNEUMONIA, VENTILATOR-ASSOCIATED; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84903907123     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc13914     Document Type: Article

References (29)

1. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK, . National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008, 29:996-1011. National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities.
2. American Thoracic Society; Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. American Thoracic Society; Infectious Diseases Society of America.
3. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012, 54:621-629.
4. Mangino JE, Peyrani P, Ford KD, Kett DH, Zervos MJ, Welch VL, Scerpella EG, Ramirez JA, . IMPACT-HAP Study Group Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study. Crit Care 2011, 15:R38. IMPACT-HAP Study Group.
5. Kett DH, Cano E, Quartin AA, Mangino JE, Zervos MJ, Peyrani P, Cely CM, Ford KD, Scerpella EG, Ramirez JA, . Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 2011, 11:181-189. Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators.
6. Centers for Disease Control and Prevention Ventilator-associated pneumonia (VAP) event [National Healthcare Safety Network manual patient safety component protocol: device-assisted events]. Available from: [http://www.cdc.gov/nhsn/PDFs/pscManual/6pscVAPcurrent.pdf]. Accessed 11 June 2013., Centers for Disease Control and Prevention.
7. Austin P. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Communications in Statistics-Simulation and Computation 2009, 38:1228-1234.
8. Ho D, Imai K, King G, Stuart E. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw 2011, 42:1-28.
9. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998, 280:1690-1691.
10. Bender R, Belettner M. Calculating the " number needed to be exposed" with adjustment for confounding variables in epidemiological studies. J Clin Epidemiol 2002, 55:525-530.
11. Sekhon J. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw 2011, 42:1-52.
12. Sampf S. Nonrandom: stratification and matching by the propensity score [R software add-on package]. Version 1.4. Available from: [http://CRAN.R-project.org/package=nonrandom]. Accessed 11 June 2013.
13. Mebane W, Sekhon J. Genetic optimization using derivatives: the rgenoud package for R. J Stat Softw 2011, 42:1-26.
14. Fox J, Weisberg S. An R Companion to Applied Regression 2011, Sage: Thousand Oaks, CA, 2.
15. Owen M, Imai K, King G, Lau O. Zelig: everyone's statistical software [R software add-on package]. Version 4.1-1. Available from: [http://CRAN.R-project.org/package=Zelig]. Accessed 11 June 2013.
16. Urbanek S, Horner J. Cairo: R graphics device using cairo graphics library for creating high-quality bitmap (PNG, JPEG, TIFF), vector (PDF, SVG, PostScript) and display (X11 and Win32) output [R software add-on package]. Version 1.5-2. Available from: http://CRAN.R-project.org/package=Cairo. Accessed 11 June 2013.
17. Therneau T. A package for survival analysis in S [R software add-on package]. Available from: [http://CRAN.R-project.org/package=survival]. Accessed 11 June 2013.
18. Harrell F. Hmisc: Harrell miscellaneous [R software add-on package]. Version 3.10-1. Available from: [http://CRAN.R-project.org/package=Hmisc]. Accessed 11 June 2013.
19. Segarra-Newnham M, Church TJ. Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Ann Pharmacother 2012, 46:1678-1687.
20. Rubinstein E, Cammarata S, Oliphant T, Wunderink R, . Linezolid Nosocomial Pneumonia Study Group Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001, 32:402-412. Linezolid Nosocomial Pneumonia Study Group.
21. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004, 30:388-394.
22. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH, . Linezolid Nosocomial Pneumonia Study Group Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003, 25:980-992. Linezolid Nosocomial Pneumonia Study Group.
23. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124:1789-1797.
24. Haque NZ, Cahuayme Zuniga L, Peyrani P, Peyrani P, Reyes K, Lamerato L, Moore CL, Patel S, Allen M, Peterson E, Wiemken T, Cano E, Mangino JE, Kett DH, Ramirez JA, Zervos MJ, . Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010, 138:1356-1362. Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Investigators.
25. Boselli E, Breilh D, Rimmele T, Djabarouti S, Toutain J, Chassard D, Saux MC, Allaouchiche B. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med 2005, 33:1529-1533.
26. Timsit JF, Zahar JR, Chevret S. Attributable mortality of ventilator-associated pneumonia. Curr Opin Crit Care 2011, 17:464-471.
27. Melsen WG, Rovers MM, Koeman M, Bonten MJ. Estimating the attributable mortality of ventilator-associated pneumonia from randomized prevention studies. Crit Care Med 2011, 39:2736-2742.
28. Bekaert M, Timsit JF, Vansteelandt S, Depuydt P, Vésin A, Garrouste-Orgeas M, Decruyenaere J, Clec'h C, Azoulay E, Benoit D, . Outcomerea Study Group Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. Am J Respir Crit Care Med 2011, 184:1133-1139. Outcomerea Study Group.
29. Kollef MH, Hamilton CW, Ernst FR. Economic impact of ventilator-associated pneumonia in a large matched cohort. Infect Control Hosp Epidemiol 2012, 33:250-256.